2-Chloropyridine

2-Chloropyridine

SCHEMBL989587

Clc1ccccn1.O=S(=O)(Cl)Cl

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.80
KDM4E B2RXH2 4/20 0.47
PKM P14618 1/20 0.47
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NFE2L2 Q16236 4/20 0.43
LMNA P02545 2/20 0.43
CCR1 P32246 2/20 0.42
CCR5 P51681 2/20 0.42
CCR8 P51685 2/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
METAP1 P53582 1/20 0.42
BLM P54132 1/20 0.42
HIF1A Q16665 1/20 0.42
DOHH Q9BU89 1/20 0.42
P4HTM Q9NXG6 1/20 0.42
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTGS2 P35354 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Chloropyridine SCHEMBL7008866 0.91 TDP1 (0.73) TDP1KDM4EPKMALDH1A1HSD17B10
2-Chloropyridine SCHEMBL16637 0.89
2-Chloropyridine SCHEMBL28283275 0.89 TDP1 (1.00) TDP1KDM4EPKMALDH1A1HSD17B10
2-Chloropyridine SCHEMBL10690176 0.89 TDP1 (1.00) TDP1KDM4EPKMALDH1A1HSD17B10
2-Chloropyridine SCHEMBL29402311 0.89
2-Chloropyridine SCHEMBL11389784 0.89
2-Chloropyridine SCHEMBL27864521 0.87
2-Chloropyridine SCHEMBL932532 0.87
2-Chloropyridine SCHEMBL8545796 0.87
2-Chloropyridine SCHEMBL5751999 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119143705-A Benzofuran lymph specific tyrosine phosphatase inhibitor and preparation method and application thereof 山东大学 2024-12-17 CN claimed
CN-119143705-A Benzofuran lymph specific tyrosine phosphatase inhibitor and preparation method and application thereof 山东大学 2024-12-17 CN disclosed
US-8957089-B2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG (DE) 2015-02-17 US disclosed
CN-101039904-B Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders ABBOTT GMBH & CO KG 2014-09-24 CN disclosed
CN-102083797-B Tetrahydroisoquinolines, pharmaceutical compositions containing them and their use in therapy ABBOTT GMBH & CO KG 2014-06-04 CN disclosed
US-8653100-B2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2014-02-18 US disclosed
US-20130203749-A1 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2013-08-08 US disclosed
CN-103224487-A Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBOTT GMBH & CO KG 2013-07-31 CN disclosed
EP-2271625-B1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO KG (DE) 2012-09-12 EP disclosed
CN-102083797-A Tetrahydroisoquinolines, pharmaceutical compositions containing them and their use in therapy ABBOTT GMBH & CO KG 2011-06-01 CN disclosed
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott BmbH & Co. KG (DE) 2011-05-05 US disclosed
EP-2271625-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott GmbH & Co. KG (DE) 2011-01-12 EP disclosed
CN-101910131-A Carboxamide, sulfonamide and amine compounds for metabolic disorders RIGEL PHARMACEUTICALS INC 2010-12-08 CN disclosed
WO-2009121872-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO. KG (DE) 2009-10-08 WO disclosed
CN-101039904-A Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders ABBOTT GMBH & CO KG (DE) 2007-09-19 CN disclosed
EP-1048654-B1 Process for the preparation of chloropyridine sulfonyl chloride RUETGERS ORGANICS GMBH (DE) 2003-07-30 EP disclosed
EP-1048654-A3 Process for the preparation of chloropyridine sulfonyl chloride Rütgers Organics GmbH (DE) 2000-11-08 EP disclosed
EP-1048654-A2 Process for the preparation of chloropyridine sulfonyl chloride Rütgers Organics GmbH (DE) 2000-11-02 EP disclosed
WO-1997046553-A1 THROMBIN INHIBITORS NOVARTIS AG (CH) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY GOLT1B, SLC10A1, SUGT1 TDP1 1689/4885KDM4E 3292/4885PKM 2340/4885
US-20130203749-A1 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy GOLT1B, SLC10A1, SUGT1 TDP1 1689/4885KDM4E 3292/4885PKM 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.